Introduction: Deep vein thrombosis (DVT) is a multifactorial disease with genetic and acquired risk factors playing in concert in its pathogenesis. ApoE gene polymorphisms seem to have some impact among patients with cardiovascular disease; however, association between DVT and ApoE gene polymorphism has not been evaluated. Materials and Methods: We aimed to search the relative frequencies ApoE alleles among patients with DVT and healthy participants. We enrolled 59 consecutive patients with DVT and 59 age-and sex-matched healthy controls. Results: In the DVT group, E3/E4 gene polymorphism was detected in 20 patients (33.9%), in the control group E3/E4 polymorphism was detected in six patients (10.2%; P ¼ .002). In the multivariable regression analysis, E3/E4 was independently associated with 1.31-fold increased risk of DVT (odds ratio [OR] 1.31; 95% confidence interval [CI], 1.30-10.48). Conclusion: It seems there is a relationship between ApoE3/E4 gene polymorphism and DVT in the Turkish population. However, this pilot study should be supported with large-scale studies.
Introduction
Deep vein thrombosis (DVT) is a multifactorial medical problem with genetic and acquired risk factors playing in concert in its pathogenesis. 1 Deep vein thrombosis is known to be closely related to pulmonary embolism, a major risk factor for mortality, particularly in the elderly population. 2 Hence, accurate identification of tendencies and early intervention to prevent or to treat the process could be of paramount importance. Acquired risk factors are noted to be advanced age, prolonged hospitalization, malignancy, pregnancy, hormone administration, and surgical procedures. 3 As a result of single gene mutations in the genes responsible for the synthesis of coagulation factors, alteration in the structures and quantities of procoagulant proteins may occur. Most commonly investigated genetic factors were factor V Leiden and prothrombin G20210A. 4, 5 Apolipoprotein E (ApoE) is a member of apolipoprotein family, and its gene is located on 19q13.2. 6 It has 3 basic alleles named E2, E3, and E4. These alleles are represented by disparity in the 112th and 158th amino acids. ApoE3 contains cysteine in the 112th sequence and arginine in the 158th sequence. ApoE2 contains cysteine in both ranks while ApoE4 containing arginine. 7 These minor diversities account for considerably different results. ApoE2 allele is related to type III hyperlipoproteinemia and hyperlipidemia in the presence of diabetes or obesity. ApoE4 allele was shown to be associated with atherosclerosis, Alzheimer disease, decreased cognitive ability, and retardation in the formation of extensions of the neurons. 8 There is an already established relationship between ApoE gene polymorphism with cardiovascular diseases 9 ; in this particular study, we aimed to investigate the association between ApoE gene polymorphism and DVT.
Materials and Method
There has been no epidemiologic study concerning the frequencies of ApoE alleles among patients with DVT. The frequency of ApoE3/E4 among a community-based sample was found to be 13% in a previous study. 10 With the expectation of 3 times more common occurrence of ApoE3/E4 among patients with DVT (the highest frequency of Apo E3/E4 among patients with cardiovascular disease was reported to be 38% in a previous meta analysis) to have statistical power of 90%, we calculated the sample size 58/58 participants in each group. 9 In this case-control study, 75 consecutive patients who admitted to our clinic with the first attack of symptomatic DVT without any previous history of DVT were enrolled. Patients with previous history of overt cardiovascular disease (n ¼ 12) or malignancy (n ¼ 4) were excluded from the study. Hence, 59 patients were included in the final evaluation. As a control group, age-and sex-matched 59 healthy individuals were considered. The diagnosis of DVT was made by combining the results of Doppler ultrasound, duplex scanning, D-dimer levels, and phlebography.
Genotyping
Two milliliters of peripheral venous blood samples were taken into tubes with EDTA and stored at À20 C. Using the Invisorb Spin Stool DNA kit (Invitek, Berlin, Germany), genomic DNA analysis was performed. Using CVD StripAssay kit (ViennaLab, Labordiagnostika GmbH, Vienna, Austria), ApoE multiplex amplification was performed. Before the hybridization process, the material obtained from polymerase chain reaction (PCR; 4 mL) was evaluated with electrophoresis (1%) in terms of successful amplification. Among the products in which successful amplification was approved, 10 mL was used for reverse hybridization analysis. Utilizing ProfiBlot T48 (Tecan Trading AG, Switzerland) device, reverse hybridization process was performed.
Statistical Analysis
The data were introduced as percentage with their standard deviations (SD). Compatibility of genotype distribution to Hardy-Weinberg equilibrium was checked by w 2 test. Features of the patients such as sex, cigarette smoking, oral contraceptive use, pregnancy, history of trauma, history of surgery, duration of hospitalization, and the genotype frequencies were evaluated with w 2 test. Parametric data were compared with independent sample t test. The relationship between DVT and genetic variations was evaluated with univariate analysis. P < .05 was accepted as significant. Parameters having significant impact (P < .01) in univariate analysis were included in the multivariable logistic regression analysis.
Results
In DVT group, there were 35 men (59.3 %) and 24 women (40.6 %), and the mean age was 53.97 + 16.52 years. In control group, there were 30 men (50.8 %) and 29 women (49.2%), and the mean age was 51.56 + 15.57 years. Groups were statistically similar in terms of age and sex. The demographic and clinical data were presented in Table 1 . In the DVT group, E3/ E3 gene polymorphism was detected in 33 patients (55.9%), and E3/E4 gene polymorphism was detected in 20 patients (33.9%). In the control group, E3/E3 polymorphism was detected in 42 patients (71.2%) and E3/E4 polymorphism was detected in 6 patients (10.2%; Table 2 ). E3/E4 gene polymorphism was significantly more common in the DVT group (P ¼ .002). There were no differences among the other ApoE variations ( Table 2 ). In the univariate analysis, having E3/E4 polymorphism was associated with 3.3-fold increased risk of having DVT (95% confidence interval, 1.36-7.99). In the multivariable regression analysis, E3/E4 was independently associated with 1.31-fold increased risk of DVT (Table 3 ).
Discussion
Although it is known that genetic factors play a role in the etiology of DVT, all the leading genetic mutations have not been identified yet. Moreover, some of the known genetic mutations may display a geographical heterogeneity among different study groups. In this study, we investigated the ApoE gene polymorphism among the patients in a group of Turkish patients. We detected a significant relationship between DVT and ApoE3/E4 variation.
The frequency of ApoE allele differs among the different geographical populations. The E3 allele frequency was shown to be 91.6% in the in the Spanish population, while the frequency was shown to be 75% in Denmark. 10, 11 The frequency of the E4 allele was reported as 3.6% to 20.8% in different populations. 10, 11 Among our patients, while the frequency of E3 allele was found to be 80% in the control group and 74% in the DVT group; the frequency of E4 allele was found to be 12% in the control group and 22% in the DVT group ( Table 2) .
The function of ApoE in the transportation of vitamin K to liver is well known. 12, 13 In an in vitro study, it was shown that the ApoE4 isomer was catabolized twice faster than the ApoE3 isomer.
14 In association with this phenomenon, there were some articles in the literature mentioning about the relationship of the coumadin dosage with the ApoE genotype. 15 However, there is no general consensus concerning this issue. While, Kohnke et al 16 reported that the ApoE4 carriers were in need of a higher coumadin dosage, Visser et al 17 claimed that the patients with both ApoE3/E4 and ApoE4/E4 genotype needed lesser oral anticoagulant dosage compared with the patients with ApoE3/E3 genotype. We think that the reason of this disparity was the diversity of the populations studied. In the study of Kimmel et al, 18 it was noted that although African Americans with ApoE4 genotype needed a high coumadin dosage, they did not observe the same condition in the Caucasians. Marcourakis et al 19 proposed a relationship between the ApoE genotype and nitric oxide production and stated that the carriers of ApoE3/E4 allele were more vulnerable to oxidative stress. In our study, we detected that ApoE3/E4 gene polymorphism was significantly higher in patients with DVT.
There were some limitations of this study. This was a pilot study. We performed a post hoc power analysis with 33.9% and 10.2% frequencies of ApoE3/E4 gene polymorphism in DVT patients and controls, respectively. We calculated a statistical power of 89% with a P value of <.05. However, because there has been no epidemiologic study of Turkish population mentioning relative frequencies of ApoE alleles among patients versus healthy controls, the relative impact of our findings might differ largely according to distributions. Hence, there is a need to confirm our preliminary findings with larger samples. Additionally, because other predisposing genetic factors were not assessed, there were potential confounders in determining the risk attributed.
As a result, to the best of our knowledge, we showed, for the first time in the literature, a relationship between ApoE3/E4 gene polymorphism and DVT. However, this pilot study should be supported with large-scale studies.
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